{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:11:49Z","timestamp":1768482709454,"version":"3.49.0"},"reference-count":45,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,1,20]]},"DOI":"10.1200\/jco-25-01088","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T19:59:27Z","timestamp":1757534367000},"page":"139-142","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":true,"given":"Martin F.","family":"Kaiser","sequence":"first","affiliation":[{"name":"Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom"},{"name":"Department of Haematology, The Royal Marsden Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":true,"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"},{"name":"Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.216"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.8032"},{"key":"e_1_3_5_4_2","article-title":"Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide-dexamethasone in patients with t(11:14)-positive relapsed\/refractory multiple myeloma","author":"Mateos MV","year":"2023","unstructured":"Mateos MV, Beksac M, Dimopoulos MA, et al: Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide-dexamethasone in patients with t(11:14)-positive relapsed\/refractory multiple myeloma. International Myeloma Society 2023 Annual Meeting, 2023","journal-title":"International Myeloma Society 2023 Annual Meeting"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3735"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2185"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-317438"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.184"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.350"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020276"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22977"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611375"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01853-0"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.12"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00139-5"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18243"},{"key":"e_1_3_5_21_2","unstructured":"US Food and Drug Administration: FDA Warns about the risks associated with the investigational use of Venclexta in Multiple Myeloma. 2019"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00225"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31711-8"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00592-2"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18568"},{"key":"e_1_3_5_26_2","volume-title":"AbbVie Provides Update on VENCLEXTA\u00ae\/VENCLYXTO\u00ae (venetoclax) Multiple Myeloma Program","author":"AbbVie","year":"2019","unstructured":"AbbVie: AbbVie Provides Update on VENCLEXTA\u00ae\/VENCLYXTO\u00ae (venetoclax) Multiple Myeloma Program. 2019"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00024-7"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30954-0"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00254-X"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70129-4"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0093"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00381-1"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.20288"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5618"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00056-X"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad100"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178735"},{"key":"e_1_3_5_41_2","volume-title":"Myeloma Incidence Statistics","author":"Cancer Research UK","year":"2024","unstructured":"Cancer Research UK: Myeloma Incidence Statistics. 2024"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00397-w"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.369"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202713"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207365"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00821-7"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-01088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:59:49Z","timestamp":1768431589000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,20]]}},"alternative-id":["10.1200\/JCO-25-01088"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-01088","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}